References
  1. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, Martin PJ, Sandmaier BM, Marr KA, Appelbaum FR, Storb R, McDonald GB. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010 Nov 25;363(22):2091-2101.
  2. Svenberg P, Remberger M, Uzunel M, Mattsson J, Gustafsson B, Fjaertoft G, Sundin M, Winiarski J, Ringdén O. Improved overall survival for pediatric patients undergoing allogeneic hematopoietic stem cell transplantation - A comparison of the last two decades. Pediatr Transplant. 2016 Aug;20(5):667-674.
  3. Paix A, Antoni D, Waissi W, Ledoux MP, Bilger K, Fornecker L, Noel G. Total body irradiation in allogeneic bone marrow transplantation conditioning regimens: A review. Crit Rev Oncol Hematol. 2018 Mar;123:138-148.
  4. McDonald GB, Slattery JT, Bouvier ME, Ren S, Batchelder AL, Kalhorn TF, Schoch HG, Anasetti C, Gooley T. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood. 2003 Mar 1;101(5):2043-2048.
  5. Ishida H, Adachi S, Hasegawa D, Okamoto Y, Goto H, Inagaki J, Inoue M, Koh K, Yabe H, Kawa K, Kato K, Atsuta Y, Kudo K. Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents. Pediatr Blood Cancer. 2015 May;62(5):883-889.
  6. Harada K, Tachibana T, Ohashi K, Ozawa Y, Sawa M, Kondo T, Ishikawa J, Onizuka M, Imada K, Fujisaki T, Tanaka J, Fukuda T, Atsuta Y, Kako S. The effect of melphalan dose and total body irradiation as reduced-intensity conditioning for acute lymphoblastic leukemia patients undergoing allogeneic stem cell transplantation. Leuk Lymphoma. 2019 Dec;60(14):3521-3528.
  7. Bitan M, He W, Zhang MJ, Abdel-Azim H, Ayas MF, Bielorai B, Carpenter PA, Cairo MS, Diaz MA, Horan JT, Jodele S, Kitko CL, Schultz KR, Kletzel M, Kasow KA, Lehmann LE, Mehta PA, Shah N, Pulsipher MA, Prestidge T, Seber A, Shenoy S, Woolfrey AE, Yu LC, Davies SM. Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens. Blood. 2014 Mar 6;123(10):1615-1620.
  8. Satwani P, Cooper N, Rao K, Veys P, Amrolia P. Reduced intensity conditioning and allogeneic stem cell transplantation in childhood malignant and nonmalignant diseases. Bone Marrow Transplant. 2008 Jan;41(2):173-182.
  9. Couriel DR, Saliba RM, Giralt S, Khouri I, Andersson B, de Lima M, Hosing C, Anderlini P, Donato M, Cleary K, Gajewski J, Neumann J, Ippoliti C, Rondon G, Cohen A, Champlin R. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant. 2004 Mar;10(3):178-185.
  10. Pérez-Simón JA, Díez-Campelo M, Martino R, Brunet S, Urbano A, Caballero MD, de León A, Valcárcel D, Carreras E, del Cañizo MC, López-Fidalgo J, Sierra J, San Miguel JF. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation. Br J Haematol. 2005 Aug;130(3):394-403.
  11. Oran B, Wagner JE, DeFor TE, Weisdorf DJ, Brunstein CG. Effect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2011 Sep;17(9):1327-1334.
  12. Salas MQ, Chen S, Lam W, Pasic I, Gerbitz A, Michelis FV, Kim DDH, Al-Shaibani Z, Lipton JH, Mattsson J, Kumar R, Viswabandya A, Law AD. Less Is More: Superior Graft-versus-Host Disease-Free/Relapse-Free Survival with Reduced-Intensity Conditioning and Dual T Cell Depletion in Acute Myelogenous Leukemia. Biol Blood Marrow Transplant. 2020 Aug;26(8):1511-1519.
  13. Terwey TH, Vega-Ruiz A, Hemmati PG, Martus P, Dietz E, le Coutre P, Massenkeil G, Dörken B, Arnold R. NIH-defined graft-versus-host disease after reduced intensity or myeloablative conditioning in patients with acute myeloid leukemia. Leukemia. 2012 Mar;26(3):536-542.
  14. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995 Jun;15(6):825-828.
  15. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005 Dec;11(12):945-956.
  16. Kanda Y. Investigation of the freely available easy-to-use software ’EZR’ for medical statistics. Bone Marrow Transplant. 2013 Mar;48(3):452-458.
  17. Peters LJ, Withers HR, Cundiff JH, Dicke KA. Radiobiological considerations in the use of total-body irradiation for bone-marrow transplantation. Radiology. 1979 Apr;131(1):243-247.
  18. Wheldon TE. The radiobiological basis of total body irradiation. Br J Radiol. 1997 Dec;70(840):1204-1207.
  19. Uckun FM, Jaszcz W, Chandan-Langlie M, Waddick KG, Gajl-Peczalska K, Song CW. Intrinsic radiation resistance of primary clonogenic blasts from children with newly diagnosed B-cell precursor acute lymphoblastic leukemia. J Clin Invest. 1993 Mar;91(3):1044-1051.
  20. Dutreix J, Wambersie A, Loirette M, Boisserie G. Time factors in total body irradiation. Pathol Biol (Paris). 1979 Jun;27(6):365-9.
  21. Uckun FM, Chandan-Langlie M, Jaszcz W, Obuz V, Waddick K, Song CW. Radiation damage repair capacity of primary clonogenic blasts in acute lymphoblastic leukemia. Cancer Res. 1993 Mar 15;53(6):1431-1436.
  22. Pearson AE, Steel GG. Chemotherapy in combination with pelvic irradiation: a time-dependence study in mice. Radiother Oncol. 1984 Jun;2(1):49-55.
  23. Collis CH, Steel GG. Lung damage in mice from cyclophosphamide and thoracic irradiation: the effect of timing. Int J Radiat Oncol Biol Phys. 1983 May;9(5):685-9.
  24. Parkins CS, Whitsed CA, Fowler JF. Repair kinetics in mouse lung after multiple X-ray fractions per day. Int J Radiat Biol. 1988 Sep;54(3):429-443.
  25. Van Rongen E, Kuijpers WC, Madhuizen HT. Fractionation effects and repair kinetics in rat kidney. Int J Radiat Oncol Biol Phys. 1990 May;18(5):1093-1106.
  26. Clift RA, Buckner CD, Appelbaum FR, Bearman SI, Petersen FB, Fisher LD, Anasetti C, Beatty P, Bensinger WI, Doney K, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood. 1990 Nov 1;76(9):1867-1871.
  27. Nakasone H, Fukuda T, Kanda J, Mori T, Yano S, Kobayashi T, Miyamura K, Eto T, Kanamori H, Iwato K, Uchida N, Mori S, Nagamura-Inoue T, Ichinohe T, Atsuta Y, Teshima T, Murata M; GVHD working group of the Japan Society of Hematopoietic Cell Transplantation. Impact of conditioning intensity and TBI on acute GVHD after hematopoietic cell transplantation. Bone Marrow Transplant. 2015 Apr;50(4):559-565.
  28. Harris AC, Ferrara JL, Levine JE. Advances in predicting acute GVHD. Br J Haematol. 2013 Feb;160(3):288-302.
  29. Baron F, Baker JE, Storb R, Gooley TA, Sandmaier BM, Maris MB, Maloney DG, Heimfeld S, Oparin D, Zellmer E, Radich JP, Grumet FC, Blume KG, Chauncey TR, Little MT. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood. 2004 Oct 15;104(8):2254-2262.
  30. Kassim AA, Chinratanalab W, Ferrara JL, Mineishi S. Reduced-intensity allogeneic hematopoietic stem cell transplantation for acute leukemias: ’what is the best recipe?’. Bone Marrow Transplant. 2005 Oct;36(7):565-574.
  31. Pérez-Simón JA, Caballero D, Diez-Campelo M, Lopez-Pérez R, Mateos G, Cañizo C, Vazquez L, Vidriales B, Mateos MV, Gonzalez M, San Miguel JF. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Leukemia. 2002 Aug;16(8):1423-1431.
  32. Elkaim E, Picard C, Galambrun C, Barlogis V, Loundou A, Curtillet C, Oudin C, Thuret I, Chambost H, Michel G. Peripheral blood cells chimerism after unrelated cord blood transplantation in children: kinetics, predictive factors and impact on post-transplant outcome. Br J Haematol. 2014 Aug;166(4):557-565.
  33. Balon J, Hałaburda K, Bieniaszewska M, Reichert M, Bieniaszewski L, Piekarska A, Pawłowski R, Hellmann A. Early complete donor hematopoietic chimerism in peripheral blood indicates the risk of extensive graft-versus-host disease. Bone Marrow Transplant. 2005 Jun;35(11):1083-1088.
  34. Afram G, Simón JAP, Remberger M, Caballero-Velázquez T, Martino R, Piñana JL, Ringden O, Esquirol A, Lopez-Corral L, Garcia I, López-Godino O, Sierra J, Caballero D, Ljungman P, Vazquez L, Hägglund H. Reduced intensity conditioning increases risk of severe cGVHD: identification of risk factors for cGVHD in a multicenter setting. Med Oncol. 2018 Apr 25;35(6):79.
  35. Perruche S, Marandin A, Kleinclauss F, Angonin R, Fresnay S, Baron MH, Tiberghien P, Saas P. Association of mixed hematopoietic chimerism with elevated circulating autoantibodies and chronic graft-versus-host disease occurrence. Transplantation. 2006 Feb 27;81(4):573-582.